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Abstract
While there exists a wealth of information about genetic influences on gene expression, less is known about how inherited
variation influences the expression and post-translational modifications of proteins, especially those involved in intracellular
signaling. The PI3K/AKT/mTOR signaling pathway contains several such proteins that have been implicated in a number of
diseases, including a variety of cancers and some psychiatric disorders. To assess whether the activation of this pathway is
influenced by genetic factors, we measured phosphorylated and total levels of three key proteins in the pathway (AKT1,
p70S6K, 4E-BP1) by ELISA in 122 lymphoblastoid cell lines from 14 families. Interestingly, the phenotypes with the highest
proportion of genetic influence were the ratios of phosphorylated to total protein for two of the pathway members: AKT1
and p70S6K. Genomewide linkage analysis suggested several loci of interest for these phenotypes, including a linkage peak
for the AKT1 phenotype that contained the AKT1 gene on chromosome 14. Linkage peaks for the phosphorylated:total
protein ratios of AKT1 and p70S6K also overlapped on chromosome 3. We selected and genotyped candidate genes from
under the linkage peaks, and several statistically significant associations were found. One polymorphism in HSP90AA1 was
associated with the ratio of phosphorylated to total AKT1, and polymorphisms in RAF1 and GRM7 were associated with the
ratio of phosphorylated to total p70S6K. These findings, representing the first genomewide search for variants influencing
human protein phosphorylation, provide useful information about the PI3K/AKT/mTOR pathway and serve as a valuable
proof of concept for studies integrating human genomics and proteomics.
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Introduction
Recent advances in genetics have included large genomewide
association studies in which inherited variants have been associated
with a particular clinical outcome, such as type 2 diabetes [1–3].
However, when there is an understanding of the biological basis of a
particular disease, a potentially more tractable approach is to search
for variants that influence the physiological hallmarks of the disease
[4,5]. To this end, studies have identified variants associated with
biomarkers such as blood glucose levels for metabolic syndrome or
bone mineral density for osteoporosis [6–10].
On a more molecular level, several groups have published
analyses of genetic variation associated with mRNA expression
of most human genes, often using cell line models [11–13]. These
results have been used to identify expression quantitative trait loci
(eQTLs) and potential causal variants for additional phenotypes,
such as response to drugs or radiation [14–16]. The scientific
potential of eQTL studies rests on the idea that a gene’s mRNA
expression level is related to the expression level of its encoded
protein, which drives the phenotype in question. However, mRNA
expression levels rarely demonstrate strong correlations with
protein expression, and loci have been identified for comparatively
few human protein levels [17–22]. We could not identify any
studies that have been clearly focused on identifying genetic
influences on the post-translational modifications that can be so
critical in determining a protein’s activity. Proteins involved in cell
signaling are particularly influenced by alterations like phosphor-
ylation, so understanding genetic influences on corresponding
mRNA or total protein levels may be largely irrelevant when
considering diseases dependent on alterations of signaling.
The phosphoinositide 3-kinase/AKT/mechanistic target of
rapamycin (PI3K/AKT/mTOR) signaling pathway is well-
characterized and has been linked to the pathology of a number
of diseases. The stimulation of this pathway begins with the
activation of receptor tyrosine kinases, which promotes the
recruitment and activation of PI3K family members [23,24].
PI3Ks can additionally be activated by signaling mediated by G
protein coupled receptors and Ras [25,26]. Upon activation,
PI3Ks phosphorylate phosphotidylinositol-4,5-bisphosphate (PIP2)
to convert it to phosphotidylinositol-3,4,5-trisphosphate (PIP3), a
process opposed by PTEN [23,24]. Increased PIP3 levels cause
AKT1 to be recruited to the plasma membrane, where it is
phosphorylated and activated at Thr308 by PDPK1 and at Ser473
by mTOR complex 2 (mTORC2) [25,27,28]. AKT1 then
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mTOR complex 1 (mTORC1), which in turn phosphorylates
additional proteins, including p70 S6 kinase (p70S6K) and 4E-BP1
[29–31]. The net result of the activation of this pathway is an
increase in translation of some proteins, including key growth
regulatory proteins like cyclin D1 and MYC [30,32].
While somatic mutations in the PI3K/AKT/mTOR pathway
are common in many types of cancer, inherited variation has also
been implicated in cancer and several psychiatric diseases. For
example, PI3K/AKT/mTOR signaling is altered in models of
schizophrenia, and several single nucleotide polymorphisms
(SNPs) in the AKT1 gene have been associated with the
development of the disease as well as with total AKT1 protein
levels [33–35]. In contrast to these common SNPs, inherited rare
variants in other pathway genes, such as PTEN, TSC1 and TSC2
have long been known to cause cancer syndromes [36–38]. The
PI3K/AKT/mTOR pathway may also be involved in mediating
the response to cancer treatment; one study has claimed
associations between SNPs in several pathway genes and several
esophageal cancer outcomes including recurrence risk, survival
and treatment response [39].
Given the importance of the PI3K/AKT/mTOR pathway in
such a broad array of traits and diseases, a better understanding of
variation in its activation is essential. Utilizing a commonly used
lymphoblastoid cell line collection, we used standard protein and
human genetics techniques to conduct the first search for variants
that are associated with protein-based measures of PI3K/AKT/
mTOR activity. To our knowledge, this also represents the first
attempt at identifying variants that influence specific post-
translational modifications. Here, we present evidence for the
statistically significant associations of several SNPs with measures
of PI3K/AKT/mTOR pathway activity.
Methods
Cell culture and protein preparation
122 lymphoblastoid cell lines from 14 families in the publicly
available CEPH (Centre d’Etude du Polymorphisme Humain)
collection were seeded at a density of 250,000 cells/ml and a total
volume of 20 ml in duplicate flasks. Variation in cell culture
conditions was minimized by thawing all cell lines in a total of four
batches, growing all cell lines in the same incubator, using cell lines
within a maximum of 2 passages of each other, performing the
bulk of the cell culture over a three-week period and using cell
culture reagents with identical lot numbers. Growth media
consisted of RPMI (Invitrogen) plus 10% fetal bovine serum
(Sigma). After 48 hours, contents of duplicate flasks were pooled,
and cells were washed twice in ice-cold PBS before being
resuspended in lysis buffer (100 mM Tris, 100 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% Triton-X, 10% glycerol, 0.1% SDS,
0.5% sodium deoxycholate, all chemicals from Fisher) supple-
mented with 1 mM PMSF (Sigma) and protease and phosphatase
inhibitors (Pierce). Cell suspensions were incubated on ice for
30 minutes with periodic vortexing before centrifugation at
13,0006g at 4uC for 10 minutes. Supernatants were then
removed, applied to Vivaspin 500 concentrating columns
(Sartorius) and spun at 15,0006g at 4uC for 1 hour. Concentrated
lysates were stored at 280uC, and protein concentrations were
determined using the Bio-Rad DC Protein Assay. All cell lysates
experienced exactly one freeze-thaw cycle.
ELISAs
ELISAs were performed using kits for specifically measuring
phospho-AKT1 (pS473), total AKT1, phospho-p70S6K (pT389),
total p70S6K, phospho-4E-BP1 (pT46), and total 4E-BP1
(Invitrogen/Biosource). Each of the 122 protein samples were
assayed in triplicate when sufficient protein was available, and
recombinant protein standards and pooled lysate standards were
placed on each 96-well plate for quality control purposes. All
antibody-bound plates for each protein were from a single lot, and
additional reagents for each protein were also checked to make
sure they came from the same lot. If not, they were pooled before
use. Kit protocols were followed exactly with one exception:
protein samples were first diluted to achieve equal concentrations
before applying equal volumes of lysate to the plates. Final
absorbance at 450 nm was read using a Beckman Coulter
DTX880 plate reader. Sample information, raw data, standard
curves and other information is available upon request.
Data cleaning, heritability and linkage analysis
For each assay, we confirmed that standard curves were
acceptable and that samples fell within the range defined by the
standards. Triplicate OD readings were averaged for both the
phosphorylated and total protein ELISAs, and ratios of phos-
phorylated to total protein were calculated by dividing the
respective OD values. It should be noted that the use of antibodies
and detection reagents of varying concentrations and affinities in
the ELISA kits for phosphorylated and total proteins can produce
higher OD readings for the phosphorylated form of a protein
relative to the OD readings for its total form, resulting in a ratio
phenotype greater than 1. This does not imply that there is more
phosphorylated protein in the sample than there is total protein. In
total, results were obtained for nine measured phenotypes (total
protein, phosphorylated protein, and phosphorylated:total protein
ratio for AKT1, p70S6K and 4E-BP1). Genetic analyses were
conducted using the SOLAR software package. To adjust the data
to meet SOLAR’s requirements, each of the nine phenotypes was
assessed for normality, transformed with an inverse or logarithmic
transformation if appropriate, and multiplied by a constant. To
assess heritability for these phenotypes, polygenic models were
created in SOLAR. A handful of covariates were screened for each
phenotype, including age, sex, age6sex, age
2, age
26sex, ELISA
plate number, and protein concentration of the lysate. While initial
protein concentration was the only significant covariate for the
AKT1 ratio, five variables emerged as significant covariates for the
p70S6K ratio. These included two variables describing on which
ELISA plate the samples were measured and three variables
related to the individual’s age at the time the pedigrees were
initially obtained (age, age*sex, and age
2*sex). Since individual
ages were not available for many of the CEPH pedigrees, only 62
of 122 individuals were available to use for further analysis of the
p70S6K ratio phenotype. The ‘‘polygenic –screen’’ command was
used to screen for significant covariates and to estimate the
additive genetic heritability.
We conducted multipoint linkage analysis using SOLAR for
traits with heritability measures greater than 15%. We obtained
genotypes for 126 individuals in 14 CEPH families from version
10.0 of the CEPH genotype database, which includes both
microsatellite markers and SNPs. Genetic locations of these
markers were determined using data from the Marshfield map.
The total number of genotypes available for these markers
was 95,278 at 7,403 loci. SOLAR identified 30 markers with
Mendelian inconsistencies or other errors, and these were
removed. Before running the linkage analysis, we used the ‘‘lodadj
–calc’’ command to create a distribution of LOD scores under the
null hypothesis of no linkage. We also conducted bivariate linkage
analysis of the AKT and p70S6K phosphorylation ratios in
SOLAR. For this analysis, covariates significant for each of the
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was performed using the ‘‘polygenic –testrhog’’ command.
Candidate gene selection
Candidate genes for association analysis were selected using
CANDID, a candidate gene identification algorithm [40]. Inputs
to CANDID included unaltered output files from the linkage
analyses and a list of keywords reflecting existing knowledge about
the signaling pathway. Weights for CANDID were set as 1 for
literature, 0.2 for protein domains, 0.2 for conservation, and 0.8
for protein-protein interactions, and version 5 of the CANDID
databases was used. These weights were selected a priori based on
the nature of the phenotype under study. The literature criterion
was given the highest weight in accordance with the finding in the
original CANDID publication that it was by far the most useful of
all CANDID criteria. Protein domains and protein-protein
interactions were given higher weights than those suggested in
the CANDID publication since it seemed likely that causal genes
for these cell signaling phenotypes would encode proteins that
possess defined functional domains and that are known to interact
with some of the proteins under study here. Finally, conservation
was weighted slightly higher here as well due to the fact that this
signaling pathway is conserved across many species. The list of
keywords input to CANDID was: AKT, signaling, phosphatase,
kinase, mTOR, PI3K, phosphatidyl, phosphoinositide, p70S6K
and AKT1. Several of CANDID’s top-ranked genes were selected
for further analysis.
SNP selection, genotyping and association analysis
A total of 86 tag SNPs for six genes (HSP90AA1, KAT2B,
RAB5A, RAF1, VHL and GRM7) were selected using an r
2 cutoff
of 0.8. For AKT1, a more in-depth SNP selection process was
undertaken in which 51 coding SNPs or common intronic or
perigenic SNPs were selected from dbSNP. SNP genotyping was
performed using the Sequenom platform and DNA that had been
extracted from cell lines from the 14 CEPH families. PCR and
extension primers were designed using Sequenom AssayDesign
software (Table S1). PCR reactions, shrimp alkaline phosphatase
digestion, and extension reactions were performed according to
Sequenom’s standard protocol with one exception: a linear
adjustment to the PCR primer concentrations was made in an
attempt to standardize mass spectrometer peak heights.
Any SNP or individual that had less than an 85% success rate
was removed from further analysis. The Pedstats and MERLIN
software packages were also used to identify and remove unlikely
genotypes and genotypes that produced Mendelian errors.
Invariant SNPs were also removed. The remaining SNPs were
tested for Hardy-Weinberg equilibrium in the unrelated individ-
uals. SNPs that passed this test were analyzed in Haploview, and
several more SNPs were eliminated as having been tagged by
other genotyped SNPs. Genotypes for the remaining SNPs were
coded for analysis under an additive (genotypic) model, a
dominant model, and a recessive model. Association tests were
conducted in SAS using PROC MIXED, with pedigree ID as a
class and subject variable and compound symmetry as the
covariance structure. Significant SNPs were visualized in Haplo-
view using data from the HapMap CEU population (Version 2,
Release 24).
Results
Three proteins (AKT1, p70S6K and 4E-BP1) involved in
PI3K/AKT/mTOR signaling were assayed for this study. We
initially selected these proteins due to their robust and reliably
detectable expression levels in the cell line model used here as well
as their varying positions in the PI3K/AKT/mTOR signaling
cascade. Initial studies indicated that the ELISA assays used
showed little variation across protein samples experiencing
different numbers of freeze-thaw cycles and across protein samples
for the same cell line harvested from different cell culture flasks
(S1A, S1B). ELISA assays performed on different days using
identical protein samples gave slightly different results but
generally preserved similar relationships between cell lines (Figure
S1C). When experiments measuring two protein phenotypes were
completely redone from start to finish for a subset of cell lines, one
phenotype still showed a good correlation between replicates
(r
2=0.52), while the other did not (Figure S1D, S1E). A strong
correlation was not necessarily expected in these cases, however,
since cell line and reagent availability issues forced several key
differences between the replication experiment and the original,
including differing passage numbers for many cell lines and
differing reagent lots for the ELISAs. As mentioned above, all
possible precautions were taken to insure that samples used to
collect data points for linkage and association studies were treated
as uniformly as possible from cell culture to ELISA in order to
minimize any potential quality control issues.
Each of the three measured proteins displayed variability in the
levels of phosphorylated and total protein across the 14 families
used in this study. These measurements, as well as the derived
ratios of phosphorylated to total protein (calculated using the OD
readings for these two ELISAs), varied to different extents. For
example, p70S6K showed the lowest fold difference in total
protein (1.52-fold), while 4E-BP1 had the highest (2.43-fold). The
fold differences for measurements of phosphorylated proteins
appeared to be slightly more variable (1.99, 1.35 and 4.80 for
AKT1, p70S6K and 4E-BP1, respectively), as did the phosphor-
ylated:total ratios (2.91, 1.46 and 2.92 for AKT1, p70S6K and 4E-
BP1, respectively). Plots showing these measurements in unrelated
individuals can be found in Figure S2.
Given that variation existed in these nine phenotypes (phosphor-
ylated protein, total protein and phosphorylated:total protein for
AKT1, p70S6K and 4E-BP1), we were able to determine the
phenotypes’ heritabilities, or the percentage of variation in the traits
that can be attributed to genetic effects. We assessed normalized
phenotypes for relationshipswith anypotential covariates, including
age, sex and experimental variables. Heritabilities of the covariate-
adjusted phenotypes were generally very low (,3%) with two
exceptions: the phosphorylated:total protein ratios for two proteins,
AKT1 and p70S6K, displayed moderate heritability (Table 1,
h
2=17.99% and 23.13%, respectively). The p-value for the
heritability of the AKT1 ratio was significant (P=0.03, standard
error=0.13), but the p-value for the p70S6K ratio was not (P=0.2,
standard error=0.37), possibly due to a reduced sample size for this
phenotype. Age was determined to be a significant covariate for the
p70S6K ratio, but age information was only available for 62
individuals, so the heritability and linkage analyses was limited to
only these samples.
Since our sample sizes were relatively small and the heritabilities
for these two traits were moderate, we lacked the statistical power
necessary to conduct a genomewide association study of variants
influencing these traits. Instead, we elected to take a three-step
approach in which we first conducted conventional genomewide
linkage analyses to identify loci of interest, then identified strong
candidate genes in those regions, then tested specific variants in
those genes. The initial linkage analysis for the AKT1 and
p70S6K ratio traits failed to produce genome-wide significant
LOD scores, but there was suggestive linkage for p70S6K on
chromosome 3, with a maximum LOD score of 2.37 (Figure 1).
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presence of multiple software convergence errors in this region cast
some doubt on its reliability. For the AKT1 ratio phenotype, the
maximum LOD score was 1.70 on chromosome 14 (Figure 1).
Interestingly, there was also a smaller peak for the AKT1 ratio on
chromosome 3 (LOD=1.38 at 57 cM) close to the major peak for
the p70S6K ratio at 36 cM. Since AKT1 is known to act upstream
from p70S6K in the PI3K/AKT/mTOR pathway, it was possible
that the two peaks resulted from genetic variation in this region
that influenced one protein’s phosphorylated:total protein ratio,
which then influenced the other protein’s ratio. A bivariate
analysis revealed that the phenotypes were genetically correlated
(RhoG =0.980, P=0.009). A linkage scan for the correlated traits
identified a peak on chromosome 3 with a maximum LOD score
of 2.91, indicating that genes in this region likely influence both
traits (Figure 2). Aside from a peak on chromosome 9 in a region
with many convergence errors, no other peak exceeded a LOD
score of 2 in this genomewide scan (Figure S3). We next
incorporated each of the ratio traits as a covariate for the other
trait. This analysis resulted in retention of the peak for the AKT1
ratio but not for the p70S6K ratio (data not shown). This implied
that the causal variants in this region mainly influence the AKT1
ratio, which in turn influences the p70S6K ratio.
To search for potential positional and biological candidate
genes, we selected two regions containing linkage peaks: a region
from 87 cM to the q-terminus on chromosome 14 corresponding
to the AKT1 ratio peak, and a region from 19.5 cM to 54 cM
on chromosome 3 corresponding to the linkage peak for the
correlated AKT1 and p70S6K ratio traits. We then chose
keywords related to cell signaling and the PI3K/AKT/mTOR
pathway and entered them, along with the linkage data and other
information, into an analysis using CANDID, a candidate gene
identification algorithm [40]. CANDID scored and ranked all
genes within the defined regions, and the top ten genes for each
peak are shown in Table 2. The AKT1 gene represented an
exceptionally strong candidate for the AKT1 ratio peak on
chromosome 14, while the top-ranked genes on chromosome 3
included RAF1, VHL, and RAB5A, which are signaling proteins
in pathways that interact with PI3K/AKT/mTOR signaling
(Figure S4).
We selected the top two genes under the chromosome 14 peak
(AKT1 and HSP90AA1) and the top five genes under the
chromosome 3 peak (RAF1, VHL, KAT2B, GRM7 and RAB5A)t o
test whether variants in these genes are associated with either the
AKT1 phosphorylated:total protein ratio or the p70S6K phos-
phorylated:total protein ratio. Since the AKT1 gene was such a
strong candidate, 51 SNPs in or near AKT1 were genotyped along
with an additional 7 tag SNPs from HSP90AA1. One of these
SNPs, rs1190584, was significantly associated with the AKT1 ratio
Table 1. Heritabilities of AKT1, p70S6K and 4E-BP1
phenotypes.
Protein Phenotype Heritability (%)
AKT total 2.64
phosphorylated 2.04
phosphorylated:total 17.99
p70S6K total 2.81
phosphorylated 0
phosphorylated:total 23.13
4E-BP1 total 2.10
phosphorylated 0
phosphorylated:total 0
doi:10.1371/journal.pone.0024873.t001
Figure 1. Genomewide linkage analysis results for AKT1 and p70S6K ratio phenotypes. Genomewide linkage analysis results are shown
for the ratio of phosphorylated to total p70S6K (A) and AKT1 (B). Chromosomes 1–22 are depicted from left to right, with alternating colors indicating
different chromosomes; cM positions across each chromosome increase from left to right. The maximum LOD score for the p70S6K ratio trait is 2.37
and is found on chromosome 3, while the maximum LOD score for the AKT1 ratio is 1.70 on chromosome 14.
doi:10.1371/journal.pone.0024873.g001
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under a recessive model and 0.0042 under an additive model.
Though this SNP lies approximately 62.5 kilobases upstream of
HSP90AA1 in an intron for WDR20, it is part of a block of linkage
disequilibrium that extends into the 59 end of the HSP90AA1 gene
(Figure S5).
We tested the SNPs on chromosome 3 for association with the
phosphorylated:total p70S6K ratio because its linkage evidence in
this region was stronger than that of the phosphorylated:total
AKT1 ratio. Out of 75 tested SNPs, four showed significant
association under at least one model. Three of these (rs713178,
rs5746223 and rs9855183) are distributed across a 25-kilobase
region that includes RAF1 and are in moderately high linkage
disequilibrium with each other (Figure S5). Of the three,
rs5746223 is the only SNP located in the RAF1 gene – rs713178
and rs9855183 are both located downstream of RAF1, in introns of
the MKRN2 gene. The fourth significant SNP, rs12630300, is in
the intron of the GRM7 gene and is separated from the RAF1 SNPs
by approximately 6 megabases. These four SNPs were highly
significant, with P-values ranging from 4.10610
24 to 6.35610
25.
No other SNPs approached significant association with this
phenotype.
Discussion
Variation in the activation of the PI3K/AKT/mTOR pathway
has been linked to a variety of human diseases. In an in vitro model
using lymphoblastoid cell lines from the Centre d’Etude du
Polymorphisme Humain (CEPH) collection, we confirmed
variation in the amounts of total and phosphorylated AKT1,
p70S6K and 4E-BP1. The degree of genetic influence on the
phosphorylation of these three proteins appears to be similar to
analogous results using gene expression and protein phenotypes.
In cell lines from the CEPH collection, approximately 30% of
differentially expressed genes appear to have significant heritabil-
ity, and heritability is high (greater than 60%) for only 10% of
these genes [5,12,41]. In contrast to the wealth of expression data
available, information on protein expression is more scarce.
Handfuls of proteins have been measured in blood samples,
including C-reactive protein, serum insulin and fibrinogen, and
heritabilities for these traits range from 18–60% [42,43].
Heritability data for protein phenotypes in human cell lines is
even scarcer. One study was identified in which the heritability of
a specific protein (chromogranin B) was determined, and the
results were highly variable and dependent on which cleavage
product was measured (h
2=0.378–0.910) [44]. A more recent
study examined 544 protein phenotypes in 24 cell lines and found
only 24 of these phenotypes to have an estimated heritability
greater than 50% [21].
Given that relatively few gene and protein expression
phenotypes are strongly heritable, the finding presented here of
low heritability for the total levels of AKT1, p70S6K and 4E-BP1
is not surprising. Additionally, the two heritability levels observed
for the ratios of phosphorylated to total AKT1 and p70S6K
(17.99% and 23.13%, respectively) fall within the range of h
2
values observed for other gene and protein expression phenotypes.
It is also interesting to note that both of the heritable phenotypes
identified in this study are ratios. It is possible that by taking a ratio
of two measurements, some experimental sample-to-sample noise
is eliminated, reducing the overall variation and increasing the
heritability. In fact, a study of metabolic phenotypes identified
stronger genetic associations when considering ratios of metabo-
lites rather than single metabolite measurements [45]. Intriguingly,
total AKT levels were not very heritable at all (2.64%) in this study
(Table 1). Since this trait does not appear to be genetically
influenced, it is unlikely that this dataset would confirm the
associations between AKT1 SNPs and total protein levels reported
by other groups [33–35]. This could reflect differences in
experimental platforms (cell lines vs. tissue samples) or detection
methods (immunoblotting vs. ELISAs).
The two phenotypes with moderate heritabilities produced
interesting, though not statistically significant, linkage analysis
results. In general, it may be that their lower LOD scores are
reflective of the small sample size used in these experiments; the
use of additional CEPH pedigrees might have increased the LOD
score of these peaks. The secondary peak for the AKT1 phenotype
on chromosome 3 initially seemed to be too low to accept
statistically. However, when it was considered in tandem with the
p70S6K phenotype that mapped to the same area, the traits were
found to share a genetic component that produced a much higher
joint LOD score of 2.91 in the same area. Given what is known
about the architecture of the PI3K/AKT/mTOR signaling
pathway, this result is highly plausible biologically. A variant in
this region that significantly influences the ratio of phosphorylated
to total AKT1 would likely also produce a change in the ratio of
Figure 2. Linkage to chromosome 3 of correlated AKT1 and
p70S6K ratio phenotypes. We found the AKT1 and p70S6K ratio
traits to be genetically correlated, and we used their shared genetic
component for genomewide linkage analysis. A section of chromosome
3 containing the maximum LOD score of 2.91 is shown here.
doi:10.1371/journal.pone.0024873.g002
Table 2. Top ten identified candidate genes for the AKT1 and
p70S6K phosphorylated:total protein ratio phenotypes.
Rank
Chromosome 14
gene symbols
(CANDID score)
Chromosome 3 gene symbols
(CANDID score)
1 AKT1 (55.5) RAF1 (69.4)
2 HSP90AA1 (54.2) VHL (20.6)
3 CALM1 (33.6) KAT2B (16.7)
4 TRAF3 (17.2) GRM7 (11.2)
5 EVL (12.2) RAB5A (11.4)
6 TSHR (9.9) THRB (9.7)
7 MTA1 (9.3) IRAK2 (8.4)
8 BEGAIN (9.1) ATP2B2 (7.7)
9 CCNK (8.7) SH3BP5 (7.5)
10 YY1 (7.9) PPARG (7.2)
doi:10.1371/journal.pone.0024873.t002
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the mTOR-mediated phosphorylation and activation of p70S6K.
The disappearance of the chromosome 3 linkage peak for p70S6K
when AKT1 levels are included as a covariate confirms this
directionality. This represents evidence that this cell-based
platform for genetic analysis can confirm existing biology as well
as be used to uncover new information.
Through association tests, we identified potentially novel roles
for several genes known to influence PI3K/AKT/mTOR
signaling. HSP90, the protein product of HSP90AA1, has long
been known to affect signaling by regulating the stability of a
variety of proteins, including AKT1 [46,47]. As such, it is a
popular target for recent oncology drug development efforts
[48,49]. However, little is known about natural variation within
the HSP90AA1 gene and its effects on the activity of HSP90.
Additional investigation of the HSP90AA1 SNP that was significant
in this study, rs1190584, is necessary in order to identify the
mechanism by which a potential variant in the HSP90AA1 region
affects the ratio of phosphorylated to total AKT1. Since AKT1
must be localized at the plasma membrane in order to be
phosphorylated at residue S473, possible mechanisms include
methods by which altered HSP90 activity might inhibit this
localization. If a causal variant in this region is found to work by
altering the activity or overall levels of HSP90, it may influence
patient response to the new HSP90 inhibitors and could be
considered for future pharmacogenomic studies.
The RAF1 gene encodes RAF1 (also known as c-RAF), a key
member of the mitogen-activated protein kinase (MAPK)
signaling cascade. Though the PI3K/AKT/mTOR and MAPK
pathways are usually thought of as distinct, cross-talk between
them has been documented in a variety of contexts [50–52].
However, reports describing the mechanism for this cross-talk
are contradictory. If a functional variant in RAF1 can be shown
to influence the ratio of phosphorylated to total AKT1, its
method of influencing RAF1 expression levels or RAF1 protein
structure could help elucidate the mechanism for PI3K/AKT/
mTOR-MAPK cross-talk. As with HSP90, RAF1 represents a
target for oncology drug discovery, and additional information
gained about its mechanism could assist with the development
or testing of new treatments. A clearly necessary first step in
exploring these associations is to confirm them in another cell
line collection.
Though cell line collections have proven quite useful in work
conducted by our group and others, there are obvious limitations
to their use. Cell lines are convenient to work with but cannot
substitute for freshly obtained tissue samples in terms of their
ability to reflect real physiology. There are also potential issues
with cell lines transformed using Epstein Barr virus (EBV), like
those used for this work. The viral integration sites are not known
for these cell lines and in some cases may have caused aberrant
activation or inhibition of nearby genes. In this scenario,
variation in DNA due to EBV integration could well be
influencing the traits measured here, but since this is not
inherited, it would manifest as environmental variation, lowering
the resulting heritability estimates. Cell lines also behave
differently as they go through an increasing number of passages,
so careful attempts must be made to utilize cell lines of similar
passage number and thereby minimize environmental variation.
Variation in culture media and supplements should also be
minimized by using reagents from identical lots. For cell signaling
phenotypes like those measured here, this is especially important,
since serum concentration and culture conditions can affect these
phenotypes. If heritability estimates are decreased sufficiently by
these types of effects, some phenotypes that are truly influenced
by inherited variation may be erroneously dismissed as non-
genetic. Regardless of these caveats and in the absence of more
convenient platforms, cell culture work continues to produce
intriguing results that should be investigated more closely using
other techniques.
The work presented here represents a unique and successful
genomic method for exploring inter-individual variation in cell
signaling. With high-throughput platforms for measuring protein
levels and post-translational modifications on the horizon, this
method will be a simple, straightforward way in which to identify
biologically significant variants that may be relevant to any field in
which cell signaling is important, including cancer and psychiatric
disease research.
Supporting Information
Figure S1 Sources of biological and technical variation
in ELISA assay results. The protein phenotypes measured by
ELISA varied little after several freeze-thaw cycles, only beginning
to vary after 4 cycles (representative data shown in A). Likewise,
there was little variation in measurements produced when cell lines
were split across multiple flasks and processed separately through
the ELISA measurements (representative data shown in B). ELISA
assays performed on different days tended to give slightly different
readings (C). However, for linkage and association studies, it is
most essential that the relationships between samples remain
preserved, and this was generally seen (representative data shown
in C). A complete replication of the ELISA experiments for the
phospho-AKT/total AKT (D) and phospho-p70S6K/total
p70S6K ratios (E) was undertaken in a subset of cell lines. For
this replication, many cell lines were grown at a different passage
number than they were originally. Additionally, the ELISA kits
used for this replication were of different lot numbers than those
used for the original experiment (a known source of across-
Table 3. SNPs significantly associated with phosphorylated:total AKT1 ratio or phosphorylated:total p70S6K ratio.
Phenotype SNP Gene symbol Additive model Dominant model Recessive model
AKT1 ratio rs1190584 HSP90AA1 0.0042* 0.564 0.0036*
p70S6K ratio rs12630300 GRM7 4.10610
24 * - 4.10610
24 *
p70S6K ratio rs5746223 RAF1 6.35610
25 ** 6.35610
25 ** -
p70S6K ratio rs713178 RAF1 4.57610
24 * 5.65610
24 * 0.356
p70S6K ratio rs9855183 RAF1 6.35610
25 ** 6.35610
25 ** -
*Significant using false discovery rate of 5%.
**Significant at Bonferroni-corrected threshold.
doi:10.1371/journal.pone.0024873.t003
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replicated well, but the p70S6K ratio did not.
(TIFF)
Figure S2 Variation in AKT1, p70S6K and 4E-BP1
phenotypes. Measurements of three different proteins in cell
lines from 26 unrelated individuals are shown here. The proteins
are AKT1 (top row), p70S6K (middle row) and 4E-BP1 (bottom
row). The measurements are of total amounts of the protein (left
column), of the amounts of the protein phosphorylated at the site
indicated (middle column) and of the ratio of phosphorylated to
total protein (right column). Measurements were adjusted for
significant covariates before graphing and are sorted from highest
to lowest within each graph. Error bars represent standard error of
the mean (s.e.m.).
(TIF)
Figure S3 Genomewide linkage analysis results of
correlated AKT1 and p70S6K ratio phenotypes. The
maximum LOD score of 2.91 is on chromosome 3. The peak
on chromosome 9 is believed to be an artifact due to the presence
of multiple errors in that region.
(TIFF)
Figure S4 Candidate gene locations within linkage
peaks on chromosomes 3 and 14. The LOD peak on
chromosome 3 for the correlated ratios of phosphorylated to total
AKT and p70S6K is shown in (A), and the LOD peak on
chromosome 14 for the ratio of phosphorylated to total AKT1 is
shown in (B). The locations of the selected candidate genes for
each trait are depicted by vertical lines in the corresponding panel.
The chromosome 3 candidate genes, from left to right, are GRM7
(23.89 cM), VHL (30.72 cM), RAF1 (36.89 cM), RAB5A (43.07 cM)
and KAT2B (43.19 cM). The chromosome 14 genes are HSP90AA1
(131.52 cM) and AKT1 (134.3 cM). The cM values were
determined using CANDID and were calculated for each gene
by using the gene’s midpoint (in base pairs) to interpolate its
genetic location using two adjacent Marshfield map markers with
known physical locations.
(TIF)
Figure S5 Linkage disequilibrium surrounding signifi-
cant SNPs. Haploview plots showing the extent of linkage
disequilibrium surrounding significant SNPs in HSP90AA1 (A) and
RAF1 (B) are shown here. The physical locations of the SNPs in
relation to their associated genes is also depicted.
(TIFF)
Table S1 SNP genotyping primer information.
(DOC)
Table S2 All association test results for SNPs on
chromosomes 14 and 3.
(DOC)
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